Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple-negative Breast Cancer|Head and Neck Squamous Cell Carcinoma
Interventions: BIOLOGICAL: TJ107 +Pembrolizumab
Sponsor: I-Mab Biopharma Co. Ltd.